Dr Tobias Janowitz

University of Cambridge

University departments
Department of Oncology
University institutes
CRUK Cambridge Institute

Position: Clinical Lecturer
Personal home page:

PubMed journal articles - click here

Research description

Research of the host response in cancer, in particular cancer cachexia and anti-cancer immunity. Translational research, including clinical trials, early phase studies, and developement of therapeutic hypotheses.

Research Programme
Pancreatic Cancer
Tumour type interests
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Thomas R. Flint, Tobias Janowitz, Claire M. Connell, Edward W. Roberts, Alice E. Denton, Anthony P. Coll, Duncan I. Jodrell, Douglas T. Fearon. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity, Cell Metabolism, Volume 24, Issue 5, p672–684, 8 November 2016; dos: 10.1016/j.cmet.2016.10.010
Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, Dunn J, Park SH, Ford H. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data.Br J Cancer. 2016 Feb 16;114(4):381-7. doi: 10.1038/bjc.2015.452.
Lu L, Yan H, Shyam-Sundar V, Janowitz T. Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther. 2014 Sep 27;8:1539-53. doi: 10.2147/DDDT.S65963.
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7.
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110.
Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T.Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol. 2013 Aug;40(4):482-91. doi: 10.1053/j.seminoncol.2013.05.004. Review.
Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, MacNee W, Lomas DA, Riley JH, Griffin JL, Connor SC. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012 Oct 30;8(12):3125-33. doi: 10.1039/c2mb25194a.
Janowitz T. Biopharmaceuticals and monoclonal antibodies in oncology trials--a cross-sectional analysis. Protein Eng Des Sel. 2011 Jan;24(1-2):105-11. doi: 10.1093/protein/gzq090. Epub 2010 Oct 30.
Janowitz T, Menon DK. Exploring new routes for neuroprotective drug development in traumatic brain injury. Sci Transl Med. 2010 Apr 14;2(27):27rv1. doi: 10.1126/scitranslmed.3000330.